|
US5591855A
(en)
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
KR20000070751A
(ko)
|
1997-02-05 |
2000-11-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
US20040006074A1
(en)
|
1998-04-28 |
2004-01-08 |
The Government Of The United States Of America |
Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
|
|
AU778735B2
(en)
|
1998-06-16 |
2004-12-16 |
Centre National De La Recherche Scientifique |
Fused azepinone cyclin dependent kinase inhibitors
|
|
ATE380548T1
(de)
|
1999-01-29 |
2007-12-15 |
Univ Illinois |
Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
|
|
AU6314900A
(en)
|
1999-07-26 |
2001-02-13 |
Banyu Pharmaceutical Co., Ltd. |
Biarylurea derivatives
|
|
US6387900B1
(en)
|
1999-08-12 |
2002-05-14 |
Pharmacia & Upjohn S.P.A. |
3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
|
|
US6291504B1
(en)
|
1999-10-20 |
2001-09-18 |
Dupont Pharmaceuticals Company |
Acylsemicarbazides and their uses
|
|
US6867198B2
(en)
|
1999-12-16 |
2005-03-15 |
Eli Lilly And Company |
Agents and methods for the treatment of proliferative diseases
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
EA006153B1
(ru)
|
2000-06-26 |
2005-10-27 |
Пфайзер Продактс Инк. |
СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
|
|
DK1325011T3
(da)
|
2000-09-29 |
2004-08-16 |
Lilly Co Eli |
Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
|
|
US6706718B2
(en)
|
2000-12-01 |
2004-03-16 |
Bristol-Myers Squibb Company |
3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses
|
|
JP4302986B2
(ja)
|
2001-02-28 |
2009-07-29 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション |
細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法
|
|
WO2002092127A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Board Of Regents, The University Of Texas System |
Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
|
|
ATE314370T1
(de)
|
2002-01-22 |
2006-01-15 |
Warner Lambert Co |
2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
|
|
WO2003093469A2
(en)
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
|
MXPA05007503A
(es)
|
2003-01-17 |
2005-09-21 |
Warner Lambert Co |
Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
|
|
EA010904B1
(ru)
|
2003-05-22 |
2008-12-30 |
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. |
Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
|
|
CN1835951B
(zh)
|
2003-07-11 |
2010-06-02 |
沃尼尔·朗伯有限责任公司 |
选择性cdk4抑制剂的羟乙基磺酸盐
|
|
ES2297502T3
(es)
|
2003-10-23 |
2008-05-01 |
F. Hoffmann-La Roche Ag |
Derivados de triaza-espiropiperidinas para uso como inhibidores de glyt-1 en el tratamiento de trastornos neurologicos y neuropsiquiatricos.
|
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
|
WO2005094830A1
(en)
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
WO2005100999A2
(en)
|
2004-04-08 |
2005-10-27 |
Cornell Research Foundation, Inc. |
Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
|
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
|
EP1846408B1
(en)
|
2005-01-14 |
2013-03-20 |
Janssen Pharmaceutica NV |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
|
US20080161355A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
|
|
KR20080016659A
(ko)
|
2005-05-20 |
2008-02-21 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제의 억제제로서 유용한 피롤로피리딘
|
|
US20070049591A1
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Inhibitors of MAPK/Erk Kinase
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
WO2007065820A1
(en)
|
2005-12-09 |
2007-06-14 |
F. Hoffmann-La Roche Ag |
Tricyclic amide derivatives useful for treating obesity
|
|
EP1963273A2
(en)
|
2005-12-22 |
2008-09-03 |
Wyeth a Corporation of the State of Delaware |
Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitors
|
|
JP2009532503A
(ja)
|
2006-04-05 |
2009-09-10 |
ノバルティス アクチエンゲゼルシャフト |
癌を処置するための治療剤の組合せ
|
|
US20070270362A1
(en)
|
2006-05-18 |
2007-11-22 |
The University Of Washington |
Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
|
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
AU2007333791A1
(en)
|
2006-12-14 |
2008-06-26 |
Panacea Pharmaceuticals, Inc. |
Methods of neuroprotection by cyclin-dependent kinase inhibition
|
|
WO2008079933A2
(en)
|
2006-12-22 |
2008-07-03 |
Novartis Ag |
Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
|
|
AU2008268442A1
(en)
|
2007-06-25 |
2008-12-31 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
|
|
US9259399B2
(en)
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
MX2010006457A
(es)
|
2007-12-19 |
2010-07-05 |
Amgen Inc |
Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
|
|
US8518930B2
(en)
|
2008-07-29 |
2013-08-27 |
Nerviano Medical Sciences S.R.L. |
Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent
|
|
EA019094B1
(ru)
|
2008-08-22 |
2014-01-30 |
Новартис Аг |
Пирролопиримидины и их применение
|
|
CA2738909A1
(en)
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
CN102231984A
(zh)
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
EP2429566B1
(en)
|
2009-05-13 |
2016-01-06 |
The University of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
US9040519B2
(en)
|
2010-02-18 |
2015-05-26 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
CN103429243B
(zh)
|
2010-10-25 |
2016-06-08 |
G1治疗公司 |
Cdk抑制剂
|
|
PT2635583E
(pt)
|
2010-11-02 |
2015-09-11 |
Promega Corp |
Derivados da coelenterazina e métodos de utilização da mesma
|
|
JP2013545758A
(ja)
|
2010-11-17 |
2013-12-26 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護
|
|
US8815853B2
(en)
|
2010-12-23 |
2014-08-26 |
Sanofi |
Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
|
|
DK2937349T3
(en)
*
|
2011-03-23 |
2017-02-20 |
Amgen Inc |
CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
|
|
PE20141381A1
(es)
|
2011-07-01 |
2014-10-21 |
Novartis Ag |
Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
|
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
WO2013163239A1
(en)
|
2012-04-26 |
2013-10-31 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
JP6435315B2
(ja)
|
2013-03-15 |
2018-12-05 |
ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
高活性抗新生物薬及び抗増殖剤
|
|
US20140274896A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
CA2906166C
(en)
|
2013-03-15 |
2023-03-14 |
G1 Therapeutics, Inc. |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
AU2014251028A1
(en)
|
2013-04-08 |
2015-11-05 |
Janssen Pharmaceutica Nv |
Ibrutinib combination therapy
|
|
US20160257688A1
(en)
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
WO2015084892A1
(en)
|
2013-12-02 |
2015-06-11 |
Cornell University |
Methods for treating b cell proliferative disorders
|
|
US20150297608A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016126889A1
(en)
|
2015-02-03 |
2016-08-11 |
G1 Therapeutics, Inc. |
Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
|